Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 6 studies | 34% ± 8% |
Insufficient scRNA-seq data for expression of MGAM at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 1203.64 | 89 / 89 | 70% | 16.01 | 627 / 901 |
lung | 99% | 1259.48 | 570 / 578 | 12% | 0.42 | 138 / 1155 |
spleen | 100% | 4488.15 | 240 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 81% | 14832.82 | 755 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 76% | 249.96 | 1010 / 1335 | 0% | 0 | 0 / 0 |
stomach | 42% | 164.82 | 150 / 359 | 24% | 1.10 | 70 / 286 |
breast | 36% | 78.63 | 164 / 459 | 24% | 1.56 | 269 / 1118 |
liver | 48% | 96.83 | 108 / 226 | 9% | 0.34 | 36 / 406 |
intestine | 41% | 3697.24 | 397 / 966 | 12% | 0.39 | 63 / 527 |
adipose | 49% | 242.46 | 586 / 1204 | 0% | 0 | 0 / 0 |
heart | 30% | 54.29 | 260 / 861 | 0% | 0 | 0 / 0 |
esophagus | 9% | 24.46 | 134 / 1445 | 21% | 0.64 | 38 / 183 |
uterus | 25% | 47.66 | 42 / 170 | 4% | 0.16 | 20 / 459 |
brain | 19% | 24.28 | 503 / 2642 | 9% | 0.23 | 65 / 705 |
ovary | 25% | 31.86 | 45 / 180 | 2% | 0.06 | 10 / 430 |
pancreas | 7% | 8.49 | 24 / 328 | 19% | 0.90 | 34 / 178 |
thymus | 25% | 36.58 | 166 / 653 | 1% | 0.01 | 4 / 605 |
bladder | 14% | 25.71 | 3 / 21 | 9% | 0.64 | 43 / 504 |
skin | 15% | 40.79 | 264 / 1809 | 5% | 0.53 | 23 / 472 |
prostate | 13% | 24.56 | 31 / 245 | 1% | 0.02 | 6 / 502 |
adrenal gland | 5% | 5.80 | 13 / 258 | 8% | 0.31 | 18 / 230 |
muscle | 3% | 3.54 | 26 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0005983 | Biological process | starch catabolic process |
GO_0000025 | Biological process | maltose catabolic process |
GO_1901027 | Biological process | dextrin catabolic process |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0101003 | Cellular component | ficolin-1-rich granule membrane |
GO_0004558 | Molecular function | alpha-1,4-glucosidase activity |
GO_0004339 | Molecular function | glucan 1,4-alpha-glucosidase activity |
GO_0003824 | Molecular function | catalytic activity |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
GO_0032450 | Molecular function | maltose alpha-glucosidase activity |
GO_0016160 | Molecular function | amylase activity |
Gene name | MGAM |
Protein name | Maltase-glucoamylase Maltase-glucoamylase (Alpha-1,4-glucosidase) (EC 3.2.1.20) |
Synonyms | MGAML MGA |
Description | FUNCTION: Alpha-(1,4) exo-glucosidase involved in breakdown of dietary starch oligosaccharides in small intestine. Cleaves the non-reducing alpha-(1,4)-linked glucose residue in linear dextrins with retention of anomeric center stereochemistry . Mainly hydrolyzes short length oligomaltoses having two to seven glucose residues . Can cleave alpha-(1,2), alpha-(1,3) and alpha-(1,6) glycosidic linkages with lower efficiency, whereas beta glycosidic linkages are usually not hydrolyzed . . |
Accessions | E9PEQ5 ENST00000632195.1 A0A0J9YX77 Q8TE25 A0A0J9YVZ3 ENST00000497673.5 ENST00000631981.1 ENST00000465654.5 E7EW87 O43451 ENST00000549489.6 [O43451-1] ENST00000475668.6 [O43451-2] Q8TE24 ENST00000620571.1 [O43451-1] |